<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="other"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Indian J Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Indian J Pharmacol</journal-id><journal-id journal-id-type="publisher-id">IJPharm</journal-id><journal-title-group><journal-title>Indian Journal of Pharmacology</journal-title></journal-title-group><issn pub-type="ppub">0253-7613</issn><issn pub-type="epub">1998-3751</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22529488</article-id><article-id pub-id-type="pmc">3326925</article-id><article-id pub-id-type="publisher-id">IJPharm-44-261</article-id><article-id pub-id-type="doi">10.4103/0253-7613.93864</article-id><article-categories><subj-group subj-group-type="heading"><subject>Short Communication</subject></subj-group></article-categories><title-group><article-title>A comparative effect of atorvastatin with other statins in patients of hyperlipidemia</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Jose</surname><given-names>M. Alvin</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Anandkumar</surname><given-names>S.</given-names></name><xref ref-type="aff" rid="aff2">1</xref></contrib><contrib contrib-type="author"><name><surname>Narmadha</surname><given-names>M.P.</given-names></name><xref ref-type="aff" rid="aff2">1</xref></contrib><contrib contrib-type="author"><name><surname>Sandeep</surname><given-names>M.</given-names></name><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff id="aff1">Department of Pharmacology, Swamy Vivekanandha College of Pharmacy, Elayampalayam, Tiruchengode, Namakkal Dist, Tamilnadu</aff><aff id="aff2"><label>1</label>Department of Pharmacy Practice, Swamy Vivekanandha College of Pharmacy, Elayampalayam, Tiruchengode, Namakkal Dist, Tamilnadu</aff><author-notes><corresp id="cor1"><bold>Correspondence to:</bold> Dr. M. Alvin Jose, E-mail: <email xlink:href="pharmjose73@yahoo.co.in">pharmjose73@yahoo.co.in</email></corresp></author-notes><pub-date pub-type="ppub"><season>Mar-Apr</season><year>2012</year></pub-date><volume>44</volume><issue>2</issue><fpage>261</fpage><lpage>263</lpage><history><date date-type="received"><day>06</day><month>4</month><year>2011</year></date><date date-type="rev-recd"><day>28</day><month>9</month><year>2011</year></date><date date-type="accepted"><day>14</day><month>12</month><year>2011</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Indian Journal of Pharmacology</copyright-statement><copyright-year>2012</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1"><title>Objective:</title><p>The objective of the study was to evaluate the safety and efficacy of atorvastatin compared with simvastatin and pravastatin in patients of hyperlipidemia.</p></sec><sec id="st2"><title>Materials and Methods:</title><p>This was a randomized, parallel group, open-label study conducted at KG hospital, Coimbatore, Tamilnadu, India. Twenty hyperlipidemia patients each taking atorvastatin 20 mg, pravastatin 20 mg and simvastatin 20 mg tablets were selected for the study after clinical and baseline investigations. The patients were reviewed after 3<sup>rd</sup> and 5<sup>th</sup> month of statin therapy for lipid profile. The liver enzyme levels (SGOT, SGPT, ALP), albumin, bilirubin, protein and biochemical infraction parameters (Creatine Kinase, Creatine Kinase - Myocardial Band) after 5<sup>th</sup> month of treatment with statins were also reviewed.</p></sec><sec id="st3"><title>Results:</title><p>The results showed that atorvastatin significantly reduced the lipid levels (LDL-C, TC, TG, VLDL) when compared to simvastatin and pravastatin after 3<sup>rd</sup> and 5<sup>th</sup> month of treatment. Atorvastatin increased the HDL-C levels significantly when compared to simvastatin and pravastatin after 5 months of treatment. Atorvastatin also significantly reduced the CK levels when compared to pravastatin but no increase in liver enzyme levels was observed.</p></sec><sec id="st4"><title>Conclusion:</title><p>The study showed that atorvastatin is more effective when compared to simvastatin and pravastatin in patients with hyperlipidemia.</p></sec></abstract><kwd-group><title>KEY WORDS</title><kwd>Creatine kinase</kwd><kwd>creatine kinase - myocardial band</kwd><kwd>pravastatin</kwd><kwd>simvastatin</kwd></kwd-group></article-meta></front><body><sec id="sec1-1"><title>Introduction</title><p>Hyperlipidemia is a disorder of lipoprotein metabolism, which includes a number of abnormalities such as hypercholesterolemia and hypertriglyceridemia.[<xref ref-type="bibr" rid="ref1">1</xref>] Recently World Health Organization (WHO) has declared that by 2020, 60% of cardiovascular cases will be of Indian origin.[<xref ref-type="bibr" rid="ref2">2</xref>] Statins are the first line therapy for lowering lipid levels.[<xref ref-type="bibr" rid="ref1">1</xref>] Treatment of hyperlipidemia with statins has become an integral part of management of vascular diseases.[<xref ref-type="bibr" rid="ref3">3</xref>] Statins have become the leading prescription drug.[<xref ref-type="bibr" rid="ref1">1</xref>] Indications of statins have been greatly extended over the last 5 years subsequent to the publication of many multicenter prospective trials. There are multiple statins available in the Indian market like atorvastatin, simvastatin, pravastatin, pitavastatin, fluvastatin, cerivastatin and rosuvastatin.[<xref ref-type="bibr" rid="ref4">4</xref>] Most of the trials compared the fixed-dose regimens of more intensive statin therapy with less intensive statin therapy.[<xref ref-type="bibr" rid="ref5">5</xref>] Recent studies in patients with stable coronary disease showed greater reduction in C-reactive protein (CRP) with higher dose than with lower dose of statins.[<xref ref-type="bibr" rid="ref6">6</xref>] However, various studies suggest that efficacy and safety of various statins in hyperlipidemia differs considerably.[<xref ref-type="bibr" rid="ref7">7</xref>] It is difficult for the medical practitioners to select suitable statins for their patients. Hence we have compared the efficacy and safety of atorvastatin with simvastatin and pravastatin in patients of hyperlipidemia.</p></sec><sec sec-type="materials|methods" id="sec1-2"><title>Materials and Methods</title><sec id="sec2-1"><title/><sec id="sec3-1"><title>Study Design</title><p>The randomized, open label, parallel group study was conducted at KG hospital, Coimbatore, Tamilnadu, India. This study was carried out from June 2009 to January 2010. The protocol was approved by Institutional Ethics Committee (IEC). Informed consent was obtained from the patients prior to the study.</p></sec><sec id="sec3-2"><title>Patient Selection</title><p>Twenty patients with hyperlipidemia each taking atorvastatin 20 mg or pravastatin 20 mg or simvastatin 20 mg tablets were selected for the study after clinical and baseline investigations. A family history of premature coronary heart disease (CHD) was given first priority for patient selection (includes parents and siblings). Males with age limit &#x0003c;55 years and females with age limit &#x0003c;65 years were also given first priority.[<xref ref-type="bibr" rid="ref4">4</xref>] Patient details like body mass index (BMI),[<xref ref-type="bibr" rid="ref6">6</xref>] education, occupation, smoking, alcohol intake, blood pressure,[<xref ref-type="bibr" rid="ref8">8</xref>] dietary habits and family history were also considered before selecting the patients.</p></sec><sec id="sec3-3"><title>Inclusion Criteria</title><p>Male patients (35 &#x02013; 55 years) and female patients (45 &#x02013; 65 years) having low density lipoprotein cholesterol (LDL-C) higher than130 mg/dl and triglycerides (TG) more than 250 mg/dl were included in the study.</p></sec><sec id="sec3-4"><title>Exclusion Criteria</title><p>Patients with renal and hepatic failure, diabetes mellitus (I and II), pregnancy, hypothyroidism, uncontrolled hypertension, patients who had undergone bypass surgery, patients taking other lipid lowering agents like fibrates, niacin and patients who were taking cardiac drugs like warfarin, verapamil and amiodarone were excluded from the study.</p></sec><sec id="sec3-5"><title>Study visits and treatment schedule</title><p>The patients were randomized into three groups of 20 patients each taking 20 mg of atorvastatin, simvastatin and pravastatin according to the treatment regimen. Initial readings of lipid levels like LDL, TC, TG, HDL, VLDL were taken as baseline. First review values for the lipids were taken at the end of 3<sup>rd</sup> month, and the second review values were taken at the end of 5<sup>th</sup> month. For liver enzymes and creatine kinase (CK), creatine kinase &#x02013; Myocardial Band (CK-MB) levels were taken before treatment and at the end of 5<sup>th</sup> month. Lipid parameters, liver enzymes, CK and CK-MB were measured by using autoanalyzer (Microlab-300X). Participants on the baseline were advised to take the medication according to treatment schedule.</p></sec><sec id="sec3-6"><title>Statistics</title><p>All the values were expressed in mean&#x000b1;SD. The baseline, first review and second review values of atorvastatin were compared with simvastatin and pravastatin by using one-way ANOVA followed by Tukey multiple comparison test. <italic>P</italic>&#x0003c;0.05 was considered as significant.</p></sec></sec></sec><sec id="sec1-3"><title>Results</title><p>The baseline lipid profile values showed that, there was no significant difference between the groups. Atorvastatin produced significant reduction in lipids levels in comparison with simvastatin (LDL-C <italic>P</italic>&#x0003c;0.001, TC <italic>P</italic>&#x0003c;0.001, TG <italic>P</italic>&#x0003c;0.05, VLDL <italic>P</italic>&#x0003c;0.05) and pravastatin (LDL-C <italic>P</italic>&#x0003c;0.001, TC <italic>P</italic>&#x0003c;0.001, TG <italic>P</italic>&#x0003c;0.001, VLDL <italic>P</italic>&#x0003c;0.001) in the first review [<xref ref-type="table" rid="T1">Table 1</xref>]. The atorvastatin also produced significant reduction in lipid levels in comparison with simvastatin (LDL-C <italic>P</italic>&#x0003c;0.001, TC <italic>P</italic>&#x0003c;0.001, TG <italic>P</italic>&#x0003c;0.05, VLDL <italic>P</italic>&#x0003c;0.05) and pravastatin (LDL-C <italic>P</italic>&#x0003c;0.001, TC <italic>P</italic>&#x0003c;0.001, TG <italic>P</italic>&#x0003c;0.001, VLDL <italic>P</italic>&#x0003c;0.001) in the second review [<xref ref-type="table" rid="T2">Table 2</xref>]. Atorvastatin had increased the HDL-C levels significantly in comparison with simvastatin (<italic>P</italic>&#x0003c;0.001) and pravastatin (<italic>P</italic>&#x0003c;0.001) at second review. None of these drugs increase the liver enzyme levels after 5<sup>th</sup> month of treatment. But atorvastatin significantly (<italic>P</italic>&#x0003c;0.001) reduced CK levels when compared to pravastatin [<xref ref-type="table" rid="T3">Table 3</xref>].</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Comparison of lipid profile of atorvastatin, simvastatin and pravastatin-treated groups at first review</p></caption><graphic xlink:href="IJPharm-44-261-g001"/></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Comparison of lipid profile of atorvastatin, simvastatin and pravastatin-treated groups at second review</p></caption><graphic xlink:href="IJPharm-44-261-g002"/></table-wrap><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Comparison of enzymes, albumin and bilirubin levels of atorvastatin, simvastatin and pravastatin-treated groups at second review</p></caption><graphic xlink:href="IJPharm-44-261-g003"/></table-wrap></sec><sec id="sec1-4"><title>Discussion</title><p>The study was designed to evaluate the safety and efficacy of atorvastatin compared with simvastatin and pravastatin in hyperlipidemia patients considering the previous reports of efficacy and safety of different statins. The results revealed that all three drugs (atorvastatin, simvastatin and pravastatin) reduces the lipid levels (LDL-C, TC, TG, VLDL) but atorvastatin produced significant reduction when compared to simvastatin and pravastatin in both first and second review [Tables <xref ref-type="table" rid="T1">1</xref> and <xref ref-type="table" rid="T2">2</xref>]. Our results were consistent with the results of previous authors.[<xref ref-type="bibr" rid="ref3">3</xref><xref ref-type="bibr" rid="ref4">4</xref><xref ref-type="bibr" rid="ref9">9</xref>] Our results also revealed that atorvastatin increases HDL-C levels significantly when compared to simvastatin and pravastatin at second review. In this study we have also compared the effect of atorvastatin with simvastatin and pravastatin on liver enzyme (SGOT, SGPT, ALP), bilirubin and albumin levels. The study showed that none of these drugs increase the liver enzyme levels significantly as compared with baseline value. None of these drugs damaged the liver in 5 months of treatment. These results contradicted with the results of previous studies.[<xref ref-type="bibr" rid="ref10">10</xref>] There were no serious adverse events reported in this study. The biochemical markers that are widely used in the detection of infarction are CK, a more sensitive and cardio specific isoform of this enzyme was CK-MB.[<xref ref-type="bibr" rid="ref10">10</xref>] Our study revealed that atorvastatin reduces the CK levels significantly when compared to pravastatin at second review. The present results were consistent with the result of Pasceri <italic>et al</italic>., who reported that pretreatment with atorvastatin decreases the incidence of myocardial injury during coronary intervention with placebo.[<xref ref-type="bibr" rid="ref11">11</xref>] But results of Kernsa <italic>et al</italic>., contradict our results.[<xref ref-type="bibr" rid="ref12">12</xref>] To conclude, our study revealed that atorvastatin is a more effective drug when compared to simvastatin and pravastatin in patients of hyperlipidemia. None of these drugs caused hepatotoxicity after 5 months of treatment. These results might be of value to practicing physicians while selecting suitable statins for these patients.</p></sec></body><back><fn-group><fn fn-type="supported-by"><p><bold>Source of Support:</bold> Nil.</p></fn><fn fn-type="conflict"><p><bold>Conflict of Interest:</bold> None declared.</p></fn></fn-group><ref-list><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravi</surname><given-names>GR</given-names></name><name><surname>Pradeepa</surname><given-names>R</given-names></name><name><surname>Mohan</surname><given-names>V</given-names></name></person-group><article-title>Hyperlipidemia and coronary artery disease. An Update</article-title><source>Indian Heart J</source><year>2004</year><volume>56</volume><fpage>21</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">15129785</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>T</given-names></name><name><surname>Kapoor</surname><given-names>A</given-names></name></person-group><article-title>Premature coronary artery disease in North Indians: An angiography study of 1971 patients</article-title><source>Indian Heart J</source><year>2005</year><volume>57</volume><fpage>311</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">16350676</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wierzbicki</surname><given-names>AS</given-names></name><name><surname>Lumb</surname><given-names>PJ</given-names></name><name><surname>Semra</surname><given-names>Y</given-names></name><name><surname>Chik</surname><given-names>G</given-names></name><name><surname>Christ</surname><given-names>ER</given-names></name><name><surname>Crook</surname><given-names>MA</given-names></name></person-group><article-title>Atorvastatin compared with simvastatin based therapies in the management of severe familial hyperlipidemia</article-title><source>QJM</source><year>1999</year><volume>92</volume><fpage>387</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">10627888</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fleg</surname><given-names>JL</given-names></name><name><surname>Mete</surname><given-names>M</given-names></name><name><surname>Howard</surname><given-names>BV</given-names></name><name><surname>Umans</surname><given-names>JG</given-names></name><name><surname>Roman</surname><given-names>MJ</given-names></name><name><surname>Ratner</surname><given-names>RE</given-names></name><etal/></person-group><article-title>Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: The SANDS (Stop Atherosclerosis in Native Diabetics Study) trial</article-title><source>J Am Coll Cardiol</source><year>2008</year><volume>52</volume><fpage>2198</fpage><lpage>205</lpage><pub-id pub-id-type="pmid">19095139</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Josan</surname><given-names>K</given-names></name><name><surname>Majundar</surname><given-names>SR</given-names></name><name><surname>Mcalister</surname><given-names>FA</given-names></name></person-group><article-title>The efficacy and safety of intensive statin therapy: A meta analysis randomized trials</article-title><source>CMAJ</source><year>2008</year><volume>176</volume><fpage>576</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">18299547</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>KM</given-names></name><name><surname>Odell</surname><given-names>PM</given-names></name><name><surname>Wilson</surname><given-names>PW</given-names></name><name><surname>Kannel</surname><given-names>WB</given-names></name></person-group><article-title>Cardiovascular risk profiles</article-title><source>Am Heart J</source><year>1991</year><volume>121</volume><fpage>293</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">1985385</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kinlay</surname><given-names>S</given-names></name><name><surname>Schwartz</surname><given-names>GG</given-names></name><name><surname>Olsson</surname><given-names>AG</given-names></name><name><surname>Rifai</surname><given-names>N</given-names></name><name><surname>Leslie</surname><given-names>SJ</given-names></name><name><surname>Sasiela</surname><given-names>WJ</given-names></name><etal/></person-group><article-title>High dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes</article-title><source>Circulation</source><year>2003</year><volume>26</volume><fpage>571</fpage><lpage>81</lpage></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Golomb</surname><given-names>B</given-names></name></person-group><article-title>Statins lower blood pressure</article-title><source>Arch Intern Med</source><year>2008</year><volume>184</volume><fpage>243</fpage><lpage>9</lpage></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>P</given-names></name><name><surname>Kafonek</surname><given-names>S</given-names></name><name><surname>Laurora</surname><given-names>I</given-names></name><name><surname>Hunninqhake</surname><given-names>D</given-names></name></person-group><article-title>Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (the CURVES study)</article-title><source>Am J Cardiol</source><year>1998</year><volume>81</volume><fpage>582</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">9514454</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>R</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Roger</surname><given-names>W</given-names></name><name><surname>Clivw</surname><given-names>E</given-names></name></person-group><article-title>Dyslipidemia</article-title><source>Clinical Pharmacy and Therapeutics</source><year>2003</year><edition>3rd ed</edition><publisher-loc>Edinburgh</publisher-loc><publisher-name>Churchil Livingstone</publisher-name><fpage>353</fpage><lpage>69</lpage></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasceri</surname><given-names>V</given-names></name><name><surname>Patti</surname><given-names>G</given-names></name><name><surname>Nusca</surname><given-names>A</given-names></name></person-group><article-title>Randomized trial of Atorvastatin for reduction of myocardial damage during coronary intervention</article-title><source>Circulation</source><year>2004</year><volume>110</volume><fpage>674</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">15277322</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kearnsa</surname><given-names>AK</given-names></name><name><surname>Bilbiea</surname><given-names>CL</given-names></name><name><surname>Clarkson</surname><given-names>PM</given-names></name><name><surname>Whitec</surname><given-names>M</given-names></name><name><surname>Sewright</surname><given-names>KA</given-names></name><name><surname>Gadarl</surname><given-names>M</given-names></name><etal/></person-group><article-title>The creatine kinase respose to eccentric exercise with atorvastatin 10 mg or 80 mg</article-title><source>Atherosclerosis</source><year>2008</year><volume>200</volume><fpage>121</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">18261731</pub-id></element-citation></ref></ref-list></back></article>